INVO Fertility Inc Dossier - Source-backed chat

INVO Fertility Inc

IVFNASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)1.89

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.90Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $2.3M

Enterprise Value $2.2M

Shares Outstanding 2.5M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

INVO Fertility, Inc. (NASDAQ: IVF) is undergoing a major strategic transition from a medical device manufacturer to a fertility clinic operator. While its proprietary INVOcell intravaginal culture device remains a core technology, the company is focusing on expanding its clinic footprint, recently acquiring Family Beginnings in February 2026 to bring its U.S. network to four operational clinics. However, the company faces severe financial distress, including an accumulated deficit of $91.4 million, substantial going-concern risk, and a history of complex dilutive financings. Furthermore, technical accounting errors have forced the restatement of its 2025 quarterly financials, leading to Nasdaq delinquency notices. While the clinic-operations model offers a path to recurring service revenue, the high leverage, litigation settlement obligations, and severe dilution risk warrant a cautious Hold recommendation until operational stability and financial compliance are fully established.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$20.00

Mean target$20.00

High · most bullish analyst$20.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The company fails to secure additional capital, leading to a default on its debt or the $6.0 million Pritts settlement schedule. Continued delays in financial reporting result in a Nasdaq delisting, severely limiting liquidity. Operational cash burn drains remaining reserves, forcing a restructuring or liquidation.

Base CaseCentral scenario

The company successfully integrates its newly acquired Family Beginnings clinic and drives organic growth across its four operational clinics by expanding payer access (such as joining the Progyny network). It resolves its Nasdaq compliance issues by filing restated financials and manages to raise highly dilutive but necessary capital to meet its $6.0 million Pritts settlement schedule and fund operations. Revenue grows moderately, but profitability remains elusive due to high interest expenses and corporate overhead.

Bull CaseUpside scenario

The bull case centers on the commercial expansion of the low-cost, FDA-approved INVOcell device and the integration of profitable acquired clinics (like Wisconsin Fertility Institute and Family Beginnings) into a nationwide network, significantly expanding the addressable market through partnerships like the Progyny network.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Transition to a clinic-operations model provides a clearer path to recurring service-based revenue compared to a pure device-distribution model.
Acquisition of Family Beginnings adds profitable scale, generating approximately $1.2 million in revenue and $0.2 million in net income for the TTM ended September 30, 2025.
Wisconsin Fertility Institute's entry into the Progyny network expands access to employer-sponsored patients, improving the payor mix.
Strong intellectual property protection for the modified INVOcell device, with a newly issued U.S. patent extending protection through 2040.

Key Investment Risks

Significant going-concern risk with an accumulated deficit of $91.4 million and current cash insufficient to fund operations and debt service for the next 12 months.
Severe dilution risk from a history of reverse stock splits, warrant inducements, and a proposed increase in authorized common shares from 50 million to 250 million.
Nasdaq delisting risk due to late filings of the 2025 Form 10-K and subsequent quarterly reports.
Substantial near-term cash obligations, including a $6.0 million litigation settlement schedule through December 31, 2026.
Internal control weaknesses highlighted by the need to restate three quarters of 2025 financial statements due to complex debt and equity accounting errors.

Thesis Invalidation Triggers

Delisting of common stock from the Nasdaq Capital Market.
Default on the Pritts litigation settlement payment schedule.
Inability to secure additional financing to fund operations over the next two quarters.
A decline in consolidated clinic revenues indicating failure of the organic growth strategy.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.